Who is sponsoring NCT03024216?

NCT03024216 is sponsored by University of Hawaii.

What drugs are being tested in NCT03024216?

Interventions in NCT03024216: Atezolizumab1200 mg IV, Sipuleucel-T.

What condition does NCT03024216 study?

NCT03024216 studies Prostate Cancer Metastatic.

Is NCT03024216 still recruiting?

NCT03024216 is currently completed. Last updated 26 May 2021.

Last reviewed 2021-05-26 · How we verify

NCT03024216

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Completed Phase 1 Last updated 26 May 2021

What this trial tests

Phase 1 trial testing Atezolizumab1200 mg IV in Prostate Cancer Metastatic in 37 participants. Completed in 31 December 2020.

Timeline

6 February 2017

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	University of Hawaii
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	6 February 2017
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	3 locations across United States

Drugs / interventions tested

Atezolizumab1200 mg IV — full drug profile →
Sipuleucel-T — full drug profile →

Conditions studied

Prostate Cancer Metastatic — all drugs for Prostate Cancer Metastatic →

Sponsor

University of Hawaii

Who can join

18 and older, male only, with Prostate Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to compare the safety and tolerability of sequential atezolizumab followed by sipuleucel-T (Arm 1) vs. sipuleucel-T followed by atezolizumab (Arm 2) in patients who have asymptomatic or minimally symptomatic metastatic CRPC, not previously treated with docetaxel or cabazitaxel.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.
Saxena M, Bhardwaj N. · · 2018 · cited 231× · PMID 29458962 · DOI 10.1016/j.trecan.2017.12.007
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.
He Y, Xu W, Xiao YT, Huang H, et al · · 2022 · cited 192× · PMID 35750683 · DOI 10.1038/s41392-022-01042-7
Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.
Handy CE, Antonarakis ES. · · 2018 · cited 124× · PMID 29260582 · DOI 10.2217/fon-2017-0531
Towards superior dendritic-cell vaccines for cancer therapy.
Saxena M, Balan S, Roudko V, Bhardwaj N. · · 2018 · cited 99× · PMID 30116654 · DOI 10.1038/s41551-018-0250-x
Past, Current, and Future of Immunotherapies for Prostate Cancer.
Boettcher AN, Usman A, Morgans A, VanderWeele DJ, et al · · 2019 · cited 89× · PMID 31572678 · DOI 10.3389/fonc.2019.00884
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer.
Isaacsson Velho P, Antonarakis ES. · · 2018 · cited 82× · PMID 29641940 · DOI 10.1080/17512433.2018.1464388
Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer.
Sutherland SIM, Ju X, Horvath LG, Clark GJ. · · 2021 · cited 74× · PMID 33854509 · DOI 10.3389/fimmu.2021.641307
Immune Checkpoint Inhibitors in Prostate Cancer.
Venkatachalam S, McFarland TR, Agarwal N, Swami U. · · 2021 · cited 71× · PMID 34063238 · DOI 10.3390/cancers13092187

Verify or expand the search:

Other recruiting trials for Prostate Cancer Metastatic

Currently open trials in the same condition.

NCT07292168 — A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Ex · Phase 1, PHASE2 · recruiting
NCT06165302 — Exercise in Prostate Cancer · NA · recruiting
NCT07484971 — Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria · recruiting
NCT06972628 — Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 · Phase 2 · recruiting
NCT07089550 — PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN) · recruiting

Other University of Hawaii trials

Trials by the same sponsor.

NCT06964633 — The Ku Ola Project: Enhancing Health Promotion Among Native Hawaiian Men. · NA · not yet recruiting
NCT07038317 — A Text Messaging Trial to Test Vaping Health Messages Optimized to Young Adults' Vaping Status · NA · not yet recruiting
NCT07075575 — Quit-Smoking Study for Native Hawaiians · NA · not yet recruiting
NCT07075120 — Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer · Phase 1 · not yet recruiting
NCT06978790 — Generative Artificial Intelligence Nurse Staffing Study · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03024216 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Hawaii
Last refreshed: 26 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03024216.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing